Balanced news tone
News Sentiment
XRTX sentiment intelligence
XORTX Therapeutics Inc news scored across direct company coverage, industry context, sector read-through, source quality, and freshness.
Price is moving more forcefully than the current news tone suggests.
80/100 classification confidence.
directly relevant articles
high-authority source matches
-7.6% over one week, -3.8% over four weeks, trend inactive, and below fair value.
XORTX Therapeutics (XRTX) Investor presentation Summary
Market Reaction
Price moving ahead of tone
Price is moving more forcefully than the current news tone suggests.
Sentiment Mix
Positive, neutral, negative
Relevance
Why the article matched
Sources
Coverage mix
Event Lens
What the news is about
Sentiment Trail
Score over time
News Tape
Relevant headlines
XORTX Therapeutics (XRTX) Holds Near Support in Quiet Trading Session - Factor Momentum
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 29 May 2026 07:00
- Source
- dars.gov.et
XORTX Therapeutics (XRTX) Gains 1.27% as Shares Test Key Resistance Level - Overnight Profile
- Tone
- Positive 66/100
- Event
- Market update
- Published
- 27 May 2026 07:00
- Source
- dars.gov.et
XRTX News | XORTX THERAPEUTICS INC (NASDAQ:XRTX)
This article provides recent news and stock information for XORTX Therapeutics Inc. (NASDAQ: XRTX). It highlights the current stock price, after-hours trading, and recent press releases, including the closing and announcement of a US$5 million public offering.
- Tone
- Negative 39/100
- Event
- Market update
- Published
- 27 May 2026 05:09
- Source
- ChartMill
XORTX Therapeutics Company Profile & Introduction
This entry serves as a company profile and introduction for XORTX Therapeutics.
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 22 May 2026 16:39
- Source
- Moomoo
XORTX Announces Closing of US$5 Million Public Offering
XORTX Therapeutics Inc. has closed a public offering of common shares and pre-funded warrants, raising US$5 million. The company plans to use the net proceeds for working capital, general corporate purposes, and investor relations activities, including a US$2.5 million payment to
- Tone
- Positive 66/100
- Event
- Market update
- Published
- 20 May 2026 01:39
- Source
- GlobeNewswire
XORTX Therapeutics Raises US$5 Million Via Public Offering
- Tone
- Positive 58/100
- Event
- Market update
- Published
- 19 May 2026 12:15
- Source
- MT Newswires
E.F. Hutton & Co. Serves as Exclusive Placement Agent on XORTX Therapeutics Inc. $5 Million Public Offering
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 18 May 2026 15:20
- Source
- GlobeNewswire
There May Be Reason For Hope In Puma Biotechnology's (NASDAQ:PBYI) Disappointing Earnings
- Tone
- Negative 34/100
- Event
- Earnings
- Published
- 15 May 2026 07:00
- Source
- simplywall.st
XORTX Therapeutics Raising US$5 Million in a Public Offering; Shares Down 8.9%
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 14 May 2026 18:17
- Source
- MT Newswires
XORTX Announces US$5 Million Public Offering
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 14 May 2026 11:00
- Source
- GlobeNewswire
Puma Biotechnology's (NASDAQ:PBYI) Conservative Accounting Might Explain Soft Earnings
- Tone
- Neutral 50/100
- Event
- Earnings
- Published
- 14 May 2026 07:00
- Source
- Market source
Puma Biotechnology, Inc. (NASDAQ:PBYI) Analysts Are Pretty Bullish On The Stock After Recent Results
- Tone
- Positive 66/100
- Event
- Earnings
- Published
- 11 May 2026 07:00
- Source
- simplywall.st
Earnings Update: Here's Why Analysts Just Lifted Their Puma Biotechnology, Inc. (NASDAQ:PBYI) Price Target To US$5.00
- Tone
- Neutral 50/100
- Event
- Earnings
- Published
- 11 May 2026 07:00
- Source
- Market source
Q4 Earnings Highlights: Regeneron (NASDAQ:REGN) Vs The Rest Of The Biotechnology Stocks
- Tone
- Neutral 50/100
- Event
- Earnings
- Published
- 25 Apr 2026 07:00
- Source
- Market source
XORTX Meets Nasdaq Continued Listing Requirements
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 21 Apr 2026 07:00
- Source
- Market source
XORTX Therapeutics jumps as it confirms Nasdaq bid-price compliance after reverse split | XRTX Stock News
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 21 Apr 2026 07:00
- Source
- Quiver Quantitative
Biotechnology Stocks Q3 Results: Benchmarking Natera (NASDAQ:NTRA)
- Tone
- Neutral 50/100
- Event
- Earnings
- Published
- 21 Apr 2026 07:00
- Source
- Market source
A Look Back at Biotechnology Stocks’ Q4 Earnings: Incyte (NASDAQ:INCY) Vs The Rest Of The Pack
- Tone
- Neutral 50/100
- Event
- Earnings
- Published
- 29 Mar 2026 07:00
- Source
- TradingView
Xortx Therapeutics (XRTX) Stock Price, News & Analysis
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 25 Apr 2025 02:10
- Source
- Stock Titan
XORTX Therapeutics Inc. (XRTX) Stock Forecast & Price Prediction 2026–2030
- Tone
- Neutral 50/100
- Event
- Guidance
- Published
- 16 Mar 2023 22:52
- Source
- CoinCodex
What is the current Price Target and Forecast for XORTX Therapeutics (XRTX)
- Tone
- Neutral 50/100
- Event
- Guidance
- Published
- 31 Aug 2022 19:07
- Source
- Zacks Investment Research